We found that RAD52 readily partitions into phase-separated RPA droplets in vitro, and that RAD52 enrichment at sites of ALT activation is reduced in cancer cells expressing phase-separation-impaired, phosphomimetic RPA2. This evidence concerns the gene RAD52 and cancer.